Silk Road Medical, Inc (NASDAQ:SILK – Get Free Report) has been given an average recommendation of “Reduce” by the ten brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $21.50.
Several brokerages have commented on SILK. JPMorgan Chase & Co. raised their price target on shares of Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, May 1st. Argus lowered shares of Silk Road Medical from a “buy” rating to a “sell” rating in a research note on Thursday, July 11th. Stifel Nicolaus restated a “hold” rating and issued a $27.50 price target (up previously from $23.00) on shares of Silk Road Medical in a research note on Wednesday, July 17th. Lake Street Capital reiterated a “hold” rating and set a $27.50 price objective (down previously from $28.00) on shares of Silk Road Medical in a research note on Tuesday, June 18th. Finally, Piper Sandler raised their price objective on shares of Silk Road Medical from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, May 1st.
Read Our Latest Analysis on Silk Road Medical
Institutional Trading of Silk Road Medical
Silk Road Medical Price Performance
SILK opened at $27.01 on Friday. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -19.72 and a beta of 1.52. Silk Road Medical has a fifty-two week low of $6.08 and a fifty-two week high of $27.19. The company’s 50-day moving average price is $24.65 and its 200 day moving average price is $19.75. The company has a quick ratio of 9.62, a current ratio of 11.05 and a debt-to-equity ratio of 0.52.
Silk Road Medical (NASDAQ:SILK – Get Free Report) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.04. The firm had revenue of $48.50 million for the quarter, compared to analyst estimates of $44.67 million. Silk Road Medical had a negative net margin of 29.02% and a negative return on equity of 35.47%. Silk Road Medical’s quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.43) earnings per share. As a group, sell-side analysts expect that Silk Road Medical will post -1.43 earnings per share for the current year.
About Silk Road Medical
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.
Further Reading
- Five stocks we like better than Silk Road Medical
- What is Forex and How Does it Work?
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Compound Interest and Why It Matters When Investing
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- How to Buy Cheap Stocks Step by Step
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.